Data Lake Evolution: A Longitudinal Overview

Data Source Platforms: The VISTA Oncology Data Lake integrates data from three primary platforms: Genomic data from Philips ISPM (IntelliSpace Precision Medicine), Cancer Registry data from NeuralFrame, and DICOM Imaging data from the Vendor Neutral Archive.

Analysis Data Sources: This analysis reflects the raw PHI data from February 2025 to August 2026.

Interactive Visualizations: All plots in this analysis are interactive. Click on legend items to show/hide data series for better exploration.

Data Coverage Summary

This longitudinal analysis tracks the growth and evolution of the VISTA Oncology Data Lake across seven data releases from February 2025 through August 2026. The dashboard monitors key metrics including:

Data Completeness, Growth, and Platform Coverage

This report summarizes how the data lake expands and matures across releases, including changes in unique patient counts, case volume, and capture of key clinical events. It also highlights data completeness indicators such as follow-up, recurrence, and documentation depth over time.

Coverage is assessed across Cancer Registry (NeuralFrame), Genomic data (Philips ISPM and OMOP variant_occurrence), Imaging data (DICOM/OMOP image occurrence and WSI), and core OMOP clinical domains to show how multi-modal data availability evolves through each release.

Key Metrics Tracked Over Time

The sections below focus on longitudinal trends in denominator growth, vital status and event recording, genomic testing and variant patterns, imaging accumulation, and release-over-release operational cadence. Together, these metrics provide a consolidated view of data acquisition, quality, and research readiness from February 2025 through August 2026.

Demographic Summary

The demographic composition of the cohort has remained relatively stable across releases.

Note†:

  • The Tumor Board definition was updated in May 2025. February 2025 data uses the original definition based on encounter type, while May 2025 to May 2026 releases use an enhanced definition based on the OMOP visit_occurrence table, where the source value for the visit contains the phrase ‘tumor board’.

  • Feb 2026 to August 2026 Philips ISPM/Genomic Data includes patients from OMOP _variant_occurrence table combined with Philips ISPM data.

Mortality Tracking

The VISTA Oncology Data Lake captures mortality information from multiple sources to support survival analysis and outcomes research. Death records are consolidated from OMOP Clinical Data Warehouse (structured clinical death dates), Stanford Cancer Registry via NeuralFrame (vital status descriptions), and Epic Clarity’s external Death reports. This multi-source approach ensures comprehensive mortality tracking across the oncology cohort.

For detailed metrics on the external death records, see the OMOP External Death Table page.

Tumor Board and Thoracic Cancer Cohorts

The VISTA Oncology Data Lake includes specialized sub-cohorts for tumor board patients and thoracic cancer cases, enabling focused research on multidisciplinary care coordination and disease-specific outcomes. These curated cohorts demonstrate the platform’s capability to support both population-level analyses and targeted clinical investigations.

Tumor Board Sub-Cohort: Patients presented at multidisciplinary tumor boards represent complex cases requiring expert consensus for treatment planning. Tumor Board encounters are defined using the OMOP visit_occurrence table, where the source value for the visit contains the phrase ‘tumor board’.

Thoracic Cancer Sub-Cohort: Focused on lung, bronchus, and thymus malignancies, this subset enables specialized research in thoracic oncology. The cohort tracks patients identified through the Stanford Cancer Registry (NeuralFrame), supporting longitudinal studies of treatment patterns and outcomes in thoracic malignancies.

Image Occurrence Modalities

The VISTA Oncology Data Lake integrates comprehensive medical imaging data, linking diagnostic images to patient clinical records through the OMOP image occurrence table. This integration enables research connecting imaging studies with clinical outcomes, treatments, and genomic profiles.

Imaging Coverage Growth: The imaging dataset has expanded dramatically from approximately 93k patients in February 2025 to over 200k patients by May 2026, representing a substantial increase in multi-modal data availability for cancer research.

Image Series and Studies: The platform captures detailed imaging metadata including study identifiers, series information, anatomic regions, and imaging modalities (CT, MRI, PET, etc.), supporting comprehensive radiomics and image-based research.

Philips ISPM Genomic Testing

The VISTA Oncology Data Lake integrates comprehensive molecular testing data from the Philips IntelliSpace Precision Medicine (ISPM) platform, beginning with the May 2025 release. This dataset includes genomic and molecular profiling results from various testing platforms including STAMP (Stanford Actionable Mutation Panel), Heme-STAMP, and FoundationOne, enabling research on precision oncology and genomic-driven treatment strategies.

Testing Platform Coverage: The ISPM dataset captures detailed molecular testing information including test types, accession numbers, order dates, and genomic aberrations across multiple assay platforms.

Research Applications: This integration supports studies of actionable mutations, variant frequencies, treatment selection based on genomic profiles, and longitudinal tracking of molecular testing patterns in cancer care.

Transition to OMOP Variant Occurrence: As of October 2025, Philips ISPM was discontinued. Genomic variant data is now captured in the OMOP _variant_occurrence table starting from August 2025, creating an overlap period (August-October 2025) where both systems contain data. The new OMOP table includes STAMP simple variants starting February 2026 and Heme-STAMP variants starting May 2026.

Data Continuity Notes:

  • Feb 2026 to August 2026 combine both Philips ISPM and OMOP _variant_occurrence sources (deduplicated)
  • OMOP _variant_occurrence currently includes STAMP (Stanford Actionable Mutation Panel for Solid Tumors) tests only. Future releases will expand to include additional test types and platforms.

Philips ISPM (May 2025 - November 2025) - Test types: STAMP, Heme-STAMP, Foundation One

OMOP Variant Occurrence

The OMOP _variant_occurrence table captures structured genomic variant data from molecular testing platforms. Starting February 2026, STAMP (Stanford Actionable Mutation Panel for Solid Tumors) simple variants are included, with Heme-STAMP variants added beginning May 2026. This table provides a standardized, longitudinal view of genomic profiling results across the oncology cohort.

Episode Table

The OMOP episode table captures treatment episodes extracted from structured clinical data, including chemotherapy regimens, treatment protocols, and care plans. Each episode encodes the plan type and treatment protocol via JSON-structured source values, supporting longitudinal analysis of treatment patterns across the oncology cohort.

Whole Slide Imaging

The OMOP _whole_slide_imaging table captures digital pathology images linked to patient records, supporting computational pathology and image-based research. The dataset includes image metadata such as specimen types, accession numbers, and file formats (JSON/TIFF), enabling integration of histopathology imaging with clinical and genomic data.